Gaucher disease type I: associated morbidities and long term efficacy of enzyme replacement therapy

de Fost, M.

Link to publication

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Correction in plasma macrophage inflammatory protein (MIP)-1β is dose dependent during the initial phase of enzyme replacement therapy of type 1 Gaucher disease

Mariëlle J. van Breemen\textsuperscript{a}, Maaike de Fost\textsuperscript{b}, Mario Maas\textsuperscript{c}, Maaike G. Wiersma\textsuperscript{b}, Carla E. M. Hollak\textsuperscript{b}, Ludger W. Poll\textsuperscript{d}, Johannes M. Aerts\textsuperscript{a}

Department of Medical Biochemistry (a), Department of Internal Medicine, Endocrinology and Metabolism (b) and Department of Radiology (c), Academic Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands
Department of Radiology (d), Heinrich-Heine University (HHU), Duesseldorf, Germany

submitted


